医学
恩替卡韦
内科学
危险系数
肝细胞癌
荟萃分析
置信区间
入射(几何)
胃肠病学
子群分析
乙型肝炎
倾向得分匹配
替诺福韦
乙型肝炎病毒
免疫学
拉米夫定
人类免疫缺陷病毒(HIV)
病毒
物理
光学
作者
Bao-Hong Yuan,Ru-Hong Li,Rong‐Rui Huo,Min Jun Li,George Papatheodoridis,Jian Hong Zhong,Bao-Hong Yuan,Ru-Hong Li,Rong‐Rui Huo,Min Jun Li,George Papatheodoridis,Jian Hong Zhong
摘要
Abstract Background and Aim Previous smaller meta‐analyses comparing the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) provided controversial results. This updated meta‐analysis aimed to reliably identify any difference in the HCC incidence between TDF‐treated or ETV‐treated CHB patients in general or in specific subgroups. Methods PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for relevant studies with hazard ratios (HRs) for HCC between TDF‐treated and ETV‐treated CHB patients. Retrieved dates ranged from January 2009 to October 2021. HRs with or without adjustment were pooled with random‐effects model. Results Twenty‐four comparative studies involving 37 771 CHB patients treated with TDF and 72 094 treated with ETV were included. TDF was associated with lower risk of HCC compared with ETV, with pooled unadjusted HR of 0.76 (95% confidence interval [CI]: 0.67–0.86) (24 studies) and adjusted HR of 0.81 (95% CI: 0.72–0.91) (21 studies). In propensity score matching cohorts, the TDF superiority was confirmed for unadjusted HR 0.83 (95% CI: 0.71–0.97) (14 studies) and was close to significance for adjusted HR (0.78, 95% CI: 0.58–1.04) (8 studies). Subgroup analyses showed that TDF was associated with lower HCC risk than ETV treatment in CHB patients who were from Asia (adjusted HR: 0.76, 95% CI: 0.66–0.87; 15 studies) or nucleos(t)ide naïve (adjusted HR:0.74, 95% CI: 0.65–0.84; 18 studies). Conclusion Current evidence from a sizable population suggests that TDF is associated with significantly lower HCC risk compared with ETV treatment in patients who are from Asia and/or nucleos(t)ide naïve.
科研通智能强力驱动
Strongly Powered by AbleSci AI